AG-120 for Chondrosarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Do I need to stop my current medications to join the trial?
The trial requires a washout period (time without taking certain medications) for some treatments. If you are taking strong CYP3A4 inducers or certain other medications, you may need to switch to different ones before starting the trial. It's best to discuss your specific medications with the trial team.
Is Ivosidenib (AG-120) safe for humans?
Ivosidenib (AG-120) has been studied for safety in patients with advanced solid tumors, including chondrosarcoma. It showed good oral exposure, was well absorbed, and had a long half-life, with no significant safety concerns across different doses. The treatment was generally well-tolerated in these studies.12345
How is the drug AG-120 (Ivosidenib) unique for treating chondrosarcoma?
AG-120 (Ivosidenib) is unique for treating chondrosarcoma because it specifically targets and inhibits mutant IDH1 enzymes, which are present in up to 65% of chondrosarcoma cases. This is significant because there are no effective systemic therapies for advanced chondrosarcoma, and Ivosidenib reduces the harmful oncometabolite D-2-hydroxyglutarate (2-HG) that these mutations produce.34678
What data supports the effectiveness of the drug AG-120 (Ivosidenib) for treating chondrosarcoma?
Ivosidenib (AG-120) is a drug that targets a specific mutation found in many chondrosarcomas, and it has shown safety and some clinical activity in patients with advanced chondrosarcoma. It is already approved for certain cases of acute myeloid leukemia, suggesting its potential effectiveness in targeting similar mutations in chondrosarcoma.236910
Who Is on the Research Team?
Ciara Kelly, MBBCh BAO
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with advanced or recurrent chondrosarcoma and an IDH1 gene mutation. Participants must have stable vital organ functions, no severe infections, not be pregnant or breastfeeding, agree to use two forms of contraception if they can reproduce, and not have used certain other treatments recently.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AG-120 for the treatment of IDH1 mutant chondrosarcoma
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AG-120
AG-120 is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Agios Pharmaceuticals, Inc.
Industry Sponsor